MX2021009285A - Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40). - Google Patents

Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).

Info

Publication number
MX2021009285A
MX2021009285A MX2021009285A MX2021009285A MX2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A MX 2021009285 A MX2021009285 A MX 2021009285A
Authority
MX
Mexico
Prior art keywords
novel
antibodies
binding
binding antibodies
human
Prior art date
Application number
MX2021009285A
Other languages
English (en)
Spanish (es)
Inventor
Gruijl Tanja Denise De
Der Vliet Johannes Jelle Van
Paul Parren
Weerdt Iris De
Aron Philip Kater
George Lodewijk Scheffer
Original Assignee
Lava Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2022494A external-priority patent/NL2022494B1/en
Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V
Publication of MX2021009285A publication Critical patent/MX2021009285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021009285A 2019-02-01 2020-01-30 Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40). MX2021009285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2022494A NL2022494B1 (en) 2019-02-01 2019-02-01 Novel CD40-binding antibodies
NL2024087 2019-10-23
PCT/NL2020/050051 WO2020159368A1 (en) 2019-02-01 2020-01-30 Novel cd40-binding antibodies

Publications (1)

Publication Number Publication Date
MX2021009285A true MX2021009285A (es) 2021-11-12

Family

ID=71840475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009285A MX2021009285A (es) 2019-02-01 2020-01-30 Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).

Country Status (11)

Country Link
US (1) US20220135694A1 (enExample)
EP (1) EP3917960A1 (enExample)
JP (2) JP2022519082A (enExample)
KR (1) KR20210141466A (enExample)
CN (1) CN113993893A (enExample)
AU (1) AU2020216250A1 (enExample)
BR (1) BR112021015238A8 (enExample)
CA (1) CA3128148A1 (enExample)
MX (1) MX2021009285A (enExample)
SG (1) SG11202108141VA (enExample)
WO (1) WO2020159368A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532807A (ja) 2020-07-08 2023-07-31 ラヴァ・セラピューティクス・エヌ・ヴイ Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
IL300517A (en) * 2020-08-14 2023-04-01 Gammadelta Therapeutics Ltd Multispecific antibodies against variable chain delta 1 on TCR
EP4259660A1 (en) * 2020-12-10 2023-10-18 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors
JP2024506682A (ja) * 2021-02-17 2024-02-14 ガンマデルタ セラピューティクス リミテッド 抗ＴＣＲδ鎖可変部１抗体
JP2024509332A (ja) 2021-02-17 2024-02-29 ガンマデルタ セラピューティクス リミテッド 多重特異性抗ＴＣＲδ可変部１抗体
AU2022292159A1 (en) 2021-06-18 2023-12-21 Autolus Limited Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases
WO2023025194A1 (zh) * 2021-08-24 2023-03-02 江苏恒瑞医药股份有限公司 Fap/cd40结合分子及其医药用途
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
CN119213028A (zh) * 2022-01-05 2024-12-27 印希比生物科学有限公司 结合γδ T细胞的多肽及其用途
CA3208653A1 (en) * 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
JP2025521865A (ja) * 2022-06-28 2025-07-10 ベイジン スターマブ バイオメド テクノロジ リミテッド 単特異性抗体および多重特異性抗体
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
WO2024092150A2 (en) * 2022-10-26 2024-05-02 Providence Health & Services - Oregon Combination therapies utilizing microbially-expanded gamma delta t cells and t cell engaging biologics
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
JP2012521768A (ja) 2009-03-27 2012-09-20 ジモジェネティクス・インコーポレイテッド 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
PL2699601T3 (pl) * 2011-04-21 2018-05-30 Bristol-Myers Squibb Company Polipeptydy przeciwciała, które antagonizują CD40
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
WO2014081202A1 (ko) 2012-11-21 2014-05-30 주식회사 파멥신 Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물
EA039086B1 (ru) 2014-04-10 2021-12-01 Лава Терапьютикс Н.В. Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity

Also Published As

Publication number Publication date
US20220135694A1 (en) 2022-05-05
SG11202108141VA (en) 2021-08-30
WO2020159368A1 (en) 2020-08-06
AU2020216250A1 (en) 2021-08-26
JP2025032324A (ja) 2025-03-11
KR20210141466A (ko) 2021-11-23
JP2022519082A (ja) 2022-03-18
EP3917960A1 (en) 2021-12-08
BR112021015238A2 (pt) 2022-02-15
BR112021015238A8 (pt) 2022-08-16
CN113993893A (zh) 2022-01-28
CA3128148A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
MX2021009285A (es) Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40).
CO2021005987A2 (es) Compuestos de anillo fusionado
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
ECSP13012368A (es) Composiciones farmacéuticas de co-cristales de tramadol y coxibs
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
ECSP11011387A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
BR112018015603A2 (pt) ?conjugado de enzimas terapêuticas, seu método de preparação, composição farmacêutica, composição para aumentar a transcitose e seu método, composição para aumentar a distribuição de tecido de uma enzima e seu método?
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
BR112019024747A2 (pt) formulações de dose fixa
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
ECSP13012893A (es) Ureas asimétricas y usos médicos de las mismas
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2016011535A (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.